The Mandatum Life and Ilmarinen-backed nanoparticle technology developer has priced a $76.7m offering that will take place in Sweden and Finland.

Nanoform, a Finland-based drug development technology provider backed by insurance firm Mandatum Life, priced its initial public offering yesterday and will raise $76.7m when it goes public on June 4.

The company will issue approximately 20.3 million shares priced at €3.45 ($3.78) and will undertake a dual listing on the Nasdaq First North Premier Growth Markets in Sweden and Finland.

Mandatum Life, financial services firm Handelsbanken Fonder, Avohoidon Tutkimussäätiö, Fjärde AP-Fonden, Keel Capital and funds managed by Sp-Fund Management…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn